Disparities exist in survival among younger patients with acute leukemia
the ONA take:
Disparities in treatment outcomes for younger patients with acute promyelocytic leukemia (APL) exist among uninsured patients and those of Hispanic and black race/ethnicity, according to a new study published online ahead of print in the journal Cancer.
For the study, researchers sought to evaluate disparities in early death and survival in children, adolescents, and young adults with APL in California in the era of all-trans-retinoic acid (ATRA) treatment.
Researchers analyzed data from the California Cancer Registry to assess the 7-day and 30-day mortality and survival in 772 patients younger than 39 years of age with APL who were diagnosed between 1988 and 2011.
Results showed that the overall 30-day mortality decreased from 26% between 1988 and 1995 to 14% between 2004 and 2011, suggesting that the odds of death in the 30 days after diagnosis were 3 times higher during the first time period than the second time period.
Researchers found that lack of insurance and Hispanic and black race/ethnicity were associated with higher early death and reduced survival, suggesting that efforts should be made to improve access to effective treatment among those patients.
Disparities in treatment outcomes for younger patients with acute promyelocytic leukemia (APL) exist.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|